GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies using proprietary platforms licensed from institutions including the NIH. Its lead candidate GEO-MVA targets mpox and smallpox, progressing toward a planned Phase 3 trial in Europe in 2026 under an expedited regulatory pathway. The company also advances oncology candidate Gedeptin® and a multi-antigen COVID-19 vaccine aimed at immunocompromised patients. GeoVax has no commercial products to date, reported a net loss of $21.5 million in 2025, and had cash reserves supporting operations into mid-2026. Significant risks include regulatory approval challenges, manufacturing scale-up, intellectual property uncertainties, competition, and the need for additional financing.